Novartis AG
NVS evidence brief
What we can confirm
- BioSniper Score:
- 9.0 / 10
- Market Cap:
- $261.73B
- Lead Asset:
- [177lu]lu-psma-617 (Phase 4)
What it means
What to watch
Prepared research question
What matters most for NVS—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · NVS
Novartis AG (NVS) is a global healthcare company with a diversified portfolio spanning innovative medicines, generics, and radioligand therapies, facing both pipeline opportunities and clinical setbacks.
Key risk: Pipeline setback
BioSniper Score
Based on 4 of 6 signals
Market Cap
$261.73B
Cash Runway
—
Lead Asset
[177lu]lu-psma-617 (Phase 4)Next Catalyst
Phase2_Start · Oct 14, 2026Financial data as of Dec 31, 2025.
Tracking 68 pipeline candidates · 449 clinical trials · 6 catalysts · 56 FDA decisions for Novartis AG.
Novartis AG (NVS) is a global healthcare company with a diversified portfolio spanning innovative medicines, generics, and radioligand therapies, facing both pipeline opportunities and clinical setbacks.
- Cash & equivalents of $11,435.0M and shareholders' equity of $46,130.0M as of 2025-12-31 [sec].
- Remibrutinib showed positive Phase III results in relapsing multiple sclerosis, with Bank of America estimating $3 billion peak annual sales potential [news · 2026-09-07] [news · 2026-09-11].
- Del-desiran failed a late-stage trial for myotonic dystrophy type 1, not showing statistically significant improvement over placebo [news · 2026-09-11].
- Partner Monte Rosa Therapeutics received a $50M milestone after first patient dosing in a Phase 2 trial of MRT-6160 (DDY391) for Sjögren's disease [news · 2026-09-13].
- Signed an exclusive global license agreement with BoomRay Pharmaceuticals for a preclinical radioligand therapy asset [news · 2026-09-25].
What works
- Remibrutinib's positive Phase III results in relapsing multiple sclerosis support planned global regulatory filings and a potential $3 billion peak sales opportunity [news · 2026-09-07] [news · 2026-09-11].
- Novartis has a deep pipeline in radioligand therapies, including the marketed Lu-17-PSMA-617 for prostate cancer and a new preclinical license from BoomRay Pharmaceuticals [pipeline] [news · 2026-09-25].
- Strong financial position with $11,435.0M in cash and $46,130.0M in shareholders' equity as of 2025-12-31 [sec].
What to weigh
- Del-desiran failed a late-stage trial for myotonic dystrophy type 1, a key pipeline candidate, raising questions about pipeline growth [news · 2026-09-11].
- Novartis faces generic pressure on older products, which could impact revenue [news · 2026-09-11].
- The remibrutinib opportunity is still subject to regulatory approval and market share capture, with no guarantee of success [news · 2026-09-07].
From the filings
Quoted directly from source documents.
Remibrutinib has potential $3 billion peak sales in MS
“Bank of America estimates that remibrutinib could generate about $3 billion in peak annual sales in multiple sclerosis alone”
News · September 7, 2026
Del-desiran failed late-stage trial
“del-desiran failed a late-stage trial for myotonic dystrophy type 1”
News · September 11, 2026
Novartis has a radioligand therapy pipeline
“Lutetium Lu 177 vipivotide tetraxetan is a radioligand therapeutic agent”
Catalyst timeline
- 2026-10-14 · Phase2_Start: A Randomized, Double-blind, Placebo-controlled, Multicenter Phase 2a/b Study Assessing the Efficacy, Safety and Tolerability of DDY391 in Participants With Active Moderate to Severe Psoriatic Arthritis — Initiation of a Phase 2a/b study for DDY391 in psoriatic arthritis, a key pipeline candidate.
- 2026-12-15 · Phase2_Start: An Open Label, Multi-center Alpelisib Roll-over Study to Assess Long-term Safety in Participants Who Have Completed a Novartis Sponsored Alpelisib (BYL719) Study and Are Judged by the Investigator to Benefit From Continued Treatment With Alpelisib. — Roll-over study to assess long-term safety of alpelisib in patients who benefited from prior treatment.
- 2027-02-08 · Phase2_Start: A Phase 2, Open-label, Single-arm Study of Ianalumab in Addition to Eltrombopag in Pediatric Patients With Primary Immune Thrombocytopenia Who Had an Insufficient Response to or Relapsed After First-line Corticosteroid Treatment (VAYHIT-P). — Phase 2 study of ianalumab in pediatric immune thrombocytopenia, a niche but important indication.
- 2027-12-30 · Phase3_Start: A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to evaLuate the effIcacy and Safety of abeLacimab in High-risk Patients With Atrial Fibrillation Who Have Been Deemed Unsuitable for Oral antiCoagulation (LILAC-TIMI 76) — Phase 3 study of abelacimab in high-risk atrial fibrillation patients, a potential new anticoagulant option.
Risks & what to watch (3)›
Key risks
- Pipeline setback — Del-desiran failed Phase III for myotonic dystrophy type 1, a key pipeline asset [news · 2026-09-11].
- Generic competition — Novartis faces generic pressure on older products, potentially impacting revenue [news · 2026-09-11].
- Regulatory uncertainty — Remibrutinib's $3B MS opportunity depends on regulatory approval and market adoption [news · 2026-09-07].
What to watch
- Regulatory filings for remibrutinib in multiple sclerosis following positive Phase III results [news · 2026-09-11].
- Progress of the Phase 2 trial for MRT-6160 (DDY391) in Sjögren's disease and potential milestones [news · 2026-09-13].
- Development of the BoomRay radioligand therapy asset under the new global license [news · 2026-09-25].
- Upcoming Phase 2 start for DDY391 in psoriatic arthritis on 2026-10-14 [catalyst].
Sources: Catalysts · News · Pipeline · Generated October 13, 2026 · How we verify sources →
Run Novartis AG through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Novartis AG facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 4 of 6 signals · derived from public data
Cash runway data unavailable
D/E 1.40
Lead: Approved
68 candidates
6 upcoming
No insider transactions in the last 180 days
Catalysts
Pipeline
Regulatory
Financials
Short Interest
as of May 21, 2026- % of float
- 0.2%
- Days to cover
- 2.9
- Shares short
- 4,488,888
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
NVS short interestGovernance
Frequently asked questions
What is the AI investment thesis for Novartis AG?
Novartis AG (NVS) is a global healthcare company with a diversified portfolio spanning innovative medicines, generics, and radioligand therapies, facing both pipeline opportunities and clinical setbacks.
What is Novartis AG's lead drug candidate?
Novartis AG's most advanced tracked candidate is [177lu]lu-psma-617 (Phase 4) for Metastatic Neuroendocrine Prostate Cancer; Metastatic Castration-Resistant Prostate Cancer (mCRPC).
What is Novartis AG's next catalyst?
Novartis AG's next tracked catalyst is a Phase2_Start event — "Phase2_Start: A Randomized, Double-blind, Placebo-controlled, Multicenter Phase 2a/b Study Assessing the Efficacy, Safety and Tolerability of DDY391 in Participants With Active Moderate to Severe Psoriatic Arthritis" — expected October 14, 2026.
Who is the CEO of Novartis AG?
Dr. Vasant Narasimhan M.D. is the chief executive officer of Novartis AG (NVS).
Where is Novartis AG headquartered?
Novartis AG (NVS) is headquartered in Basel, Switzerland.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.